source
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.BioPharma Dive · 3mo ago↗ source
- AbbVie faces questions about Skyrizi competition from J&JThreats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of the…Endpoints · 3mo ago↗ source
- FDA, AstraZeneca prep for oncology adcommThe FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the focus of the discussion. Details about the meeting of the ...